These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 26319313)

  • 1. Species and mediator specific TLR4 antagonism in primary human and murine immune cells by βGlcN(1↔1)αGlc based lipid A mimetics.
    Chebrolu C; Artner D; Sigmund AM; Buer J; Zamyatina A; Kirschning CJ
    Mol Immunol; 2015 Oct; 67(2 Pt B):636-41. PubMed ID: 26319313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-endotoxic activity and structural basis for human MD-2·TLR4 antagonism of tetraacylated lipid A mimetics based on βGlcN(1↔1)αGlcN scaffold.
    Garate JA; Stöckl J; Fernández-Alonso Mdel C; Artner D; Haegman M; Oostenbrink C; Jiménez-Barbero J; Beyaert R; Heine H; Kosma P; Zamyatina A
    Innate Immun; 2015 Jul; 21(5):490-503. PubMed ID: 25394365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tailored Modulation of Cellular Pro-inflammatory Responses With Disaccharide Lipid A Mimetics.
    Heine H; Adanitsch F; Peternelj TT; Haegman M; Kasper C; Ittig S; Beyaert R; Jerala R; Zamyatina A
    Front Immunol; 2021; 12():631797. PubMed ID: 33815382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conformationally constrained lipid A mimetics for exploration of structural basis of TLR4/MD-2 activation by lipopolysaccharide.
    Artner D; Oblak A; Ittig S; Garate JA; Horvat S; Arrieumerlou C; Hofinger A; Oostenbrink C; Jerala R; Kosma P; Zamyatina A
    ACS Chem Biol; 2013 Nov; 8(11):2423-32. PubMed ID: 23952219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neisseria meningitidis lipid A mutant LPSs function as LPS antagonists in humans by inhibiting TLR 4-dependent cytokine production.
    Sprong T; Ley Pv; Abdollahi-Roodsaz S; Joosten L; Meer Jv; Netea M; Deuren Mv
    Innate Immun; 2011 Dec; 17(6):517-25. PubMed ID: 21088052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of αGlcN(1↔1)αMan-based lipid A mimetics as a novel class of potent Toll-like receptor 4 agonists.
    Adanitsch F; Ittig S; Stöckl J; Oblak A; Haegman M; Jerala R; Beyaert R; Kosma P; Zamyatina A
    J Med Chem; 2014 Oct; 57(19):8056-71. PubMed ID: 25252784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The antagonist activity of lipid IVa on the stimulation by lipid A of TNF-alpha production from canine blood mononuclear cells.
    Takasawa K; Kano R; Maruyama H; Hasegawa A; Kamata H
    Vet Immunol Immunopathol; 2011 Sep; 143(1-2):167-9. PubMed ID: 21782253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid A Mimetics Based on Unnatural Disaccharide Scaffold as Potent TLR4 Agonists for Prospective Immunotherapeutics and Adjuvants.
    Strobl S; Hofbauer K; Heine H; Zamyatina A
    Chemistry; 2022 Jun; 28(35):e202200547. PubMed ID: 35439332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic tetra-acylated derivatives of lipid A from Porphyromonas gingivalis are antagonists of human TLR4.
    Zhang Y; Gaekwad J; Wolfert MA; Boons GJ
    Org Biomol Chem; 2008 Sep; 6(18):3371-81. PubMed ID: 18802645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural insights into pharmacophore-assisted in silico identification of protein-protein interaction inhibitors for inhibition of human toll-like receptor 4 - myeloid differentiation factor-2 (hTLR4-MD-2) complex.
    Mishra V; Pathak C
    J Biomol Struct Dyn; 2019 May; 37(8):1968-1991. PubMed ID: 29842849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationally Designed TLR4 Ligands for Vaccine Adjuvant Discovery.
    Gregg KA; Harberts E; Gardner FM; Pelletier MR; Cayatte C; Yu L; McCarthy MP; Marshall JD; Ernst RK
    mBio; 2017 May; 8(3):. PubMed ID: 28487429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toll-like receptor activation of human cells by synthetic triacylated lipid A-like molecules.
    Dunn-Siegrist I; Tissières P; Drifte G; Bauer J; Moutel S; Pugin J
    J Biol Chem; 2012 May; 287(20):16121-31. PubMed ID: 22433865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel toll-like receptor 4 (TLR4) antagonists identified by structure- and ligand-based virtual screening.
    Švajger U; Brus B; Turk S; Sova M; Hodnik V; Anderluh G; Gobec S
    Eur J Med Chem; 2013; 70():393-9. PubMed ID: 24177366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endotoxin-induced chemokine expression in murine peritoneal mesothelial cells: the role of toll-like receptor 4.
    Kato S; Yuzawa Y; Tsuboi N; Maruyama S; Morita Y; Matsuguchi T; Matsuo S
    J Am Soc Nephrol; 2004 May; 15(5):1289-99. PubMed ID: 15100369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toll-like receptor 4-dependent recognition of structurally different forms of chemically synthesized lipid As of Porphyromonas gingivalis.
    Sawada N; Ogawa T; Asai Y; Makimura Y; Sugiyama A
    Clin Exp Immunol; 2007 Jun; 148(3):529-36. PubMed ID: 17335558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cellular Toll-like receptor 4 antagonist E5531 can act as an agonist in horse whole blood.
    Bryant CE; Ouellette A; Lohmann K; Vandenplas M; Moore JN; Maskell DJ; Farnfield BA
    Vet Immunol Immunopathol; 2007 Apr; 116(3-4):182-9. PubMed ID: 17320193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD14 dependence of TLR4 endocytosis and TRIF signaling displays ligand specificity and is dissociable in endotoxin tolerance.
    Rajaiah R; Perkins DJ; Ireland DD; Vogel SN
    Proc Natl Acad Sci U S A; 2015 Jul; 112(27):8391-6. PubMed ID: 26106158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A lipid A-based TLR4 mimetic effectively adjuvants a Yersinia pestis rF-V1 subunit vaccine in a murine challenge model.
    Gregg KA; Harberts E; Gardner FM; Pelletier MR; Cayatte C; Yu L; McCarthy MP; Marshall JD; Ernst RK
    Vaccine; 2018 Jun; 36(28):4023-4031. PubMed ID: 29861179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct roles of TLR4 and CD14 in LPS-induced inflammatory responses of neonates.
    Levy E; Xanthou G; Petrakou E; Zacharioudaki V; Tsatsanis C; Fotopoulos S; Xanthou M
    Pediatr Res; 2009 Aug; 66(2):179-84. PubMed ID: 19390489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human MD-2 discrimination of meningococcal lipid A structures and activation of TLR4.
    Zimmer SM; Zughaier SM; Tzeng YL; Stephens DS
    Glycobiology; 2007 Aug; 17(8):847-56. PubMed ID: 17545685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.